Compare Biocon Ltd with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs WOCKHARDT - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON WOCKHARDT BIOCON /
WOCKHARDT
 
P/E (TTM) x 24.2 -15.1 - View Chart
P/BV x 2.7 0.7 410.7% View Chart
Dividend Yield % 0.4 0.0 6,208.8%  

Financials

 BIOCON    WOCKHARDT
EQUITY SHARE DATA
    BIOCON
Mar-19
WOCKHARDT
Mar-18
BIOCON /
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs7071,012 69.9%   
Low Rs554532 104.2%   
Sales per share (Unadj.) Rs91.9355.9 25.8%  
Earnings per share (Unadj.) Rs16.7-60.3 -27.7%  
Cash flow per share (Unadj.) Rs24.2-46.8 -51.7%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.20 12,239.3%  
Book value per share (Unadj.) Rs101.6257.8 39.4%  
Shares outstanding (eoy) m600.00110.63 542.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.2 316.4%   
Avg P/E ratio x37.7-12.8 -294.7%  
P/CF ratio (eoy) x26.1-16.5 -158.0%  
Price / Book Value ratio x6.23.0 207.3%  
Dividend payout %6.00 -36,072.7%   
Avg Mkt Cap Rs m378,33085,379 443.1%   
No. of employees `0006.16.3 98.0%   
Total wages/salary Rs m11,6539,371 124.4%   
Avg. sales/employee Rs Th8,994.36,295.0 142.9%   
Avg. wages/employee Rs Th1,900.71,498.3 126.9%   
Avg. net profit/employee Rs Th1,635.3-1,066.3 -153.4%   
INCOME DATA
Net Sales Rs m55,14439,369 140.1%  
Other income Rs m1,4441,202 120.1%   
Total revenues Rs m56,58840,571 139.5%   
Gross profit Rs m15,88318 86,792.3%  
Depreciation Rs m4,4781,495 299.5%   
Interest Rs m7092,555 27.8%   
Profit before tax Rs m12,140-2,830 -429.0%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m2,123257 826.1%   
Profit after tax Rs m10,026-6,669 -150.3%  
Gross profit margin %28.80 61,963.7%  
Effective tax rate %17.5-9.1 -192.5%   
Net profit margin %18.2-16.9 -107.3%  
BALANCE SHEET DATA
Current assets Rs m48,22833,796 142.7%   
Current liabilities Rs m30,37626,917 112.9%   
Net working cap to sales %32.417.5 185.3%  
Current ratio x1.61.3 126.5%  
Inventory Days Days6879 86.1%  
Debtors Days Days8689 95.8%  
Net fixed assets Rs m64,13039,664 161.7%   
Share capital Rs m3,000553 542.3%   
"Free" reserves Rs m57,98027,968 207.3%   
Net worth Rs m60,98028,522 213.8%   
Long term debt Rs m15,76621,731 72.6%   
Total assets Rs m121,92481,620 149.4%  
Interest coverage x18.1-0.1 -16,855.4%   
Debt to equity ratio x0.30.8 33.9%  
Sales to assets ratio x0.50.5 93.8%   
Return on assets %8.8-5.0 -174.7%  
Return on equity %16.4-23.4 -70.3%  
Return on capital %16.8-7.7 -218.3%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,5069,807 158.1%   
Fx outflow Rs m10,3991,789 581.4%   
Net fx Rs m5,1078,019 63.7%   
CASH FLOW
From Operations Rs m11,546684 1,687.0%  
From Investments Rs m-7,1386,302 -113.3%  
From Financial Activity Rs m-2,417-7,695 31.4%  
Net Cashflow Rs m2,103-664 -316.7%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.3 365.2%  
FIIs % 10.7 7.7 139.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 67,757 162.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 27, 2020 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS